# Innovo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innovo-therapeutics

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.innovothera.co.kr
- Total disclosed funding: $22M
- Latest round: Series B (Dec 22, 2021)
- Investors on record: 5

## About

Based in Seoul, South Korea, and founded in 2019, Innovo Therapeutics Inc. is a drug research and development company that utilizes artificial intelligence to find new drugs to treat various inflammatory and immunological-related diseases. In January 2022, Innovo Therapeutics Inc. raised KRW 11 billion in venture funding from Company K Partners, IMM Investment, and Tigris Investment, valuing the company at KRW 153 billion post-money. As of 2023, Innovo Therapeutics Inc. is being led by its CEO, Park Hee-dong.

The firm researches and develops synthetic drugs targeting unmet medical needs in fibrosis, immune disorders, inflammatory diseases, and cancer. The firm’s key technology is DeepZema®, an artificial intelligence platform designed for drug candidate discovery and research efficiency. DeepZema® integrates machine learning for target discovery, and ADME/toxicity prediction, and combines existing DE Novo designs with docking to create and evaluate new structures. It is used for various stages of drug research, including ligand similarity and shape-based target identification, virtual screening, lead optimization, and ADME/toxicity calculations, providing real-time results through web interface.

## Funding rounds

- Series B, Dec 22, 2021, $16M — Atinum Investment, SV Investment, Mirae Asset Venture Investment, Dong-Yu Technology Investment, Mirae Asset Capital
- Series A, Dec 28, 2019, $6M — Atinum Investment, Mirae Asset Capital

## Investors

- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series A, Series B
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series A, Series B
- SV Investment (https://capitalatlas.ai/funds/sv-investment) — Series B
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series B
- Dong-Yu Technology Investment (https://capitalatlas.ai/funds/dong-yu-technology-investment) — Series B